Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

K. Abou‐Alfa, Ghassan; Meyer, Tim; Cheng, Ann‐Lii; B. El-Khoueiry, Anthony; Rimassa, Lorenza; Ryoo, Baek‐Yeol; Çiçin, İrfan; Merle, Philippe; Chen, Yen-Hsun; Park, Joong‐Won; Blanc, Jean-Frederic; Bolondi, Luigi; Klümpen, Heinz‐Josef; L. Chan, Stephen; Zagonel, Vittorina; Pressiani, Tiziana; Ryu, Min-Hee; P. Venook, Alan; Hessel, Colin; E. Borgman-Hagey, Anne; Schwab, Gisela; Kate Kelley, Robin

doi:10.1056/nejmoa1717002

Public

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Published in New England Journal of Medicine • Jul 4, 2018

Authors:

Ghassan K. Abou‐Alfa

Tim Meyer

Ann‐Lii Cheng

Abstract

BACKGROUND: Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the standard initial treatment for advanced diseas...

Subject

Cabozantinib

Sorafenib

Hepatocellular carcinoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!